tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AKRO Stock Latest News

Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment
Company AnnouncementsAkero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment
9d ago
AKRO
Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
PremiumCompany Announcements
Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
10d ago
AKRO
Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
PremiumThe Fly
Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
15d ago
AKRO
Strong Financial Position and Promising Clinical Developments Support Buy Rating for Akero Therapeutics
PremiumRatings
Strong Financial Position and Promising Clinical Developments Support Buy Rating for Akero Therapeutics
18d ago
AKRO
Akero Therapeutics Advances in MASH Treatment Development
PremiumCompany Announcements
Akero Therapeutics Advances in MASH Treatment Development
21d ago
AKRO
Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position
PremiumRatingsRitu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position
21d ago
AKRO
Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements
Premium
Ratings
Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements
23d ago
AKRO
Video: Why Akero Therapeutics Is Trading Higher Today
Premium
The Fly
Video: Why Akero Therapeutics Is Trading Higher Today
23d ago
NVO
AKRO
Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero
PremiumThe Fly
Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero
23d ago
NVO
AKRO
AKRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
AKRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
23d ago
AKRO
Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
25d ago
AVB
BAX
Akero Therapeutics initiated with a Buy at TD Cowen
PremiumThe Fly
Akero Therapeutics initiated with a Buy at TD Cowen
25d ago
AKRO
Akero Therapeutics Advances Efruxifermin Study for NASH Treatment
PremiumCompany AnnouncementsAkero Therapeutics Advances Efruxifermin Study for NASH Treatment
28d ago
AKRO
Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Cirrhosis
Premium
Company Announcements
Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Cirrhosis
1M ago
AKRO
Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Treatment
Premium
Company Announcements
Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Treatment
1M ago
AKRO
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
PremiumCompany Announcements
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
2M ago
AKRO
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
PremiumThe Fly
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
3M ago
LLY
MRK
Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
PremiumThe Fly
Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
3M ago
CCJ
COE
Akero Therapeutics rumor highlighted in Betaville blog
PremiumThe Fly
Akero Therapeutics rumor highlighted in Betaville blog
3M ago
AKRO
Akero Therapeutics Elects New Directors at Annual Meeting
PremiumCompany AnnouncementsAkero Therapeutics Elects New Directors at Annual Meeting
3M ago
8K
AKRO
Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
Premium
Ratings
Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
3M ago
AKRO
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
3M ago
UAL
AKRO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >